Discussion on the ideal medication period of dacomitinib/dacomitinib

Dacomitinib/Dacomitinib, as an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has been widely used to treat non-small cell lung cancer. However, when is the "prime time" to take this drug? This involves considerations such as the patient's personal situation, medical advice and drug-diet interactions.

There is no fixed standard for when dacomitinib should be taken. Considering that the average absolute bioavailability of dacomitinib after oral administration is as high as 80%, and that the median time to peak plasma concentration in cancer patients after a single 45 mg ingestion is 6.0 hours (with a range of 2.0 to 24 hours), this means that each patient may have a different dosing time based on their unique situation and physician recommendations. To ensure maximum drug efficacy and minimize adverse reactions, patients should strictly follow medical instructions and try to ensure that they take the drug at a fixed time every day.

Meeting has a certain impact on the uptake and metabolism of drugs. The absorption rate of some drugs may be increased when taken with food, while the absorption of other drugs may be reduced due to food interference. Of note, administration of dacomitinib with a high-fat, high-calorie meal (approximately 800 to 1000 calories, containing 150 calories of protein, 250 calories of carbohydrate, and 500 to 600 calories of fat) did not have a clinically meaningful effect on the pharmacokinetics of dacomitinib. Therefore, patients can choose to take it on an empty stomach or after meals according to their personal circumstances and medical advice.

In addition, the taking time of dacomitinib should also take into account the patient's daily routine and eating habits. For example, if a patient is accustomed to taking their medication after breakfast, they may choose to take dacomitinib at this time. But if patients need to take medication at other times for some reason, they can be flexibly adjusted.